Browsing by Author "Sonmez, Mehmet"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey
    (2019) Beksac, Meral; Seval, Guldane Cengiz; Paydas, Semra; Tuglular, Tulin Firatli; Arslan, Onder; Goker, Hakan; Kaynar, Leylagul; Altuntas, Fevzi; Atalay, Figen; Teke, Havva Uskudar; Bolaman, Ali Zahit; Pehlivan, Mustafa; Sonmez, Mehmet; Demir, Ahmet Muzaffer; Topcuoglu, Pervin; Yilmaz, Mehmet; Kabukcu, Sibel Hacioglu; Albayrak, Murat; Yurttas, Nurgul Ozer; Salihoglu, Ayse; Cakar, Merih Kizil; Gurman, Gunhan
  • No Thumbnail Available
    Item
    Evolution of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in turkey: a multicenter retrospective analysis
    (2021) Karadag, Fatma Keklik; Yenerel, Mustafa Nuri; Yilmaz, Mehmet; Uskudar, Hava; Ozkocaman, Vildan; Tuglular, Tulin Firatli; Erdem, Fuat; Unal, Ali; Ayyildiz, Orhan; Ozet, Gulsum; Comert, Melda; Kaya, Emin; Ayer, Mesut; Salim, Ozan; Guvenc, Birol; Ozdogu, Hakan; Mehtap, Ozgur; Sonmez, Mehmet; Guler, Nil; Hacioglu, Sibel; Aydogdu, Ismet; Bektas, Ozlen; Toprak, Selami Kocak; Kaynar, Lale; Yagci, Munci; Aksu, Salih; Tombak, Anil; Karakus, Volkan; Yavasoglu, Irfan; Onec, Birgul; Ozcan, Mehmet Ali; Undar, Levent; Ali, Ridvan; Ilhan, Osman; Saydam, Guray; Sahin, Fahri; 34322292
    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab approved with promising results for PNH patients. We conducted this study to evaluate the long term experience of eculizumab therapy from Turkey for the first time. Our cohort included 138 patients with PNH treated with eculizumab between January 2008 and December 2018 at 28 centers in Turkey. Laboratory and clinical findings at the time of diagnosis and after eculizumab therapy were recorded retrospectively. The median age was 39 (range 18-84) years and median granulocyte PNH clone size was 74% (range 3.06-99.84%) at the time of diagnosis. PNH with bone marrow failure syndrome was detected in 49 patients and the rest of 89 patients had classical PNH. Overall 45 patients (32.6%) had a history of any prior thrombotic event before eculizumab therapy and only 2 thrombotic events were reported during the study period. Most common symptoms are fatigue (75.3%), hemoglobinuria (18.1%), abdominal pain (15.2%) and dysphagia (7.9%). Although PNH is commonly related with coombs negativity, we detected coombs positivity in 2.17% of patients. Seven months after the therapy, increased hemoglobin level was seen and remarkably improvement of lactate dehydrogenase level during the treatment was occurred. In addition to previous studies, our real life data support that eculizumab is well tolerated with no serious adverse events and improves the PNH related findings.
  • No Thumbnail Available
    Item
    An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
    (2021) Sevindik, Omur Gokmen; Ozkurt, Zubeyde Nur; Boga, Can; Besisik, Sevgi Kalayoglu; Ipek, Yildiz; Geduk, Ayfer; Harmandali, Aybuke; Salihoglu, Ayse; Sahin, Handan Haydaroglu; Sonmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Yuksel, Meltem Kurt; Maral, Senem; Ekinci, Omer; Kirkizlar, Hakki Onur; Tekinalp, Atakan; Demir, Nazli; Merter, Mustafa; Saydam, Guray; Alacacioglu, Inci; Yegin, Zeynep Arzu; Kasar, Mutlu; Mastanzade, Metban; Ozsan, Guner Hayri
  • Thumbnail Image
    Item
    Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4)
    (2015) Boga, Can; Bolaman, Zahit; Cagirgan, Seckin; Karadogan, Ihsan; Ozcan, Mehmet Ali; Ozkalemkas, Fahir; Saba, Rabin; Sonmez, Mehmet; Senol, Esin; Akan, Hamdi; Akova, Murat; 26316478
    This is the last of a series of articles on invasive fungal infections prepared by opinion leaders in Turkey. The aim of these articles is to guide clinicians in managing invasive fungal diseases in hematological malignancies and stem cell transplantation based on the available best evidence in this field. The previous articles summarized the diagnosis and treatment of invasive fungal disease and this article aims to explain the risk categorization and guide the antifungal prophylaxis in invasive fungal disease.